AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Plus Therapeutics Soars 32.65% on $1.6M CPRIT Payment
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jul 24, 2025 8:27 am ET1min read
Aime SummaryPlus Therapeutics' stock surged 32.65% in pre-market trading on July 24, 2025, marking a significant rise for the biotechnology company.
Plus Therapeutics has received a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT). This payment is part of a $17.6 million award granted to the company for its leptomeningeal cancer targeted radiotherapeutic development program. The advance payment is a significant milestone for
, as it indicates progress in its research and development efforts. The company's focus on targeted radiotherapeutic treatments for leptomeningeal cancer has garnered attention and support from key institutions, which could further boost investor confidence in the company's future prospects.This financial injection from CPRIT is expected to accelerate Plus Therapeutics' research and development activities, potentially leading to breakthroughs in cancer treatment. The company's commitment to innovative therapies and its strategic partnerships with leading research institutions position it well to capitalize on advancements in the field of oncology. As Plus Therapeutics continues to make strides in its development programs, investors are likely to keep a close eye on the company's progress and potential for future growth.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet